CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Search

We found 7222 result(s)

alpelisib (Piqray)

Last Updated: March 22, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: alpelisib
Indications: ​Piqray (alpelisib), in combination with fulvestrant, is indicated for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA- mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.

  • Brand Name: Piqray
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: PC0247-000
  • Project Status: Pending
  • Submission Type: Initial

Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma

Last Updated: March 22, 2021
Result type: Reports
Product Line: Therapeutic Review

Multiple myeloma (MM) is a hematological cancer that mainly affects individuals older than 65 years of age. Though MM remains incurable, several life-prolonging pharmacotherapies for the treatment of newly diagnosed, relapsed, or refractory MM were reviewed by CADTH and are available or being considered for public reimbursement in Canada. Howeve...

  • Project Number: TR0014-000
  • Project Status: In Progress

Trientine Hydrochloride (MAR-Trientine)

Last Updated: March 18, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Trientine Hydrochloride
Indications: ​MAR-Trientine (trientine hydrochloride) is indicated for the treatment of patients with Wilson's Disease who are intolerant to penicillamine. MAR-Trientine should only be initiated by physicians experienced in the management of Wilson’s Disease.

  • Brand Name: MAR-Trientine
  • Manufacturer: Marcan Pharmaceuticals Inc.
  • Project Number: SR0680-000
  • Project Status: Pending
  • Submission Type: Initial

dupilumab (Dupixent)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: dupilumab
Indications: Dupixent is indicated as an add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.

  • Brand Name: Dupixent
  • Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
  • Project Number: SR0667-000
  • Project Status: Active
  • Submission Type: Initial

risdiplam (TBC)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: risdiplam
Indications: ​For the treatment of spinal muscular atrophy (SMA)

  • Brand Name: TBC
  • Manufacturer: Hoffmann La-Roche Ltd.
  • Project Number: SR0661-000
  • Project Status: Active
  • Submission Type: Initial

pembrolizumab (Keytruda)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: pembrolizumab
Indications: ​For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)

  • Brand Name: Keytruda
  • Manufacturer: Merck Canada Inc.
  • Project Number: PC0235-000
  • Project Status: Active
  • Submission Type: Initial

luspatercept (Reblozyl )

Last Updated: March 18, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: luspatercept
Indications: Reblozyl (luspatercept for injection) is indicated for:  the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia.  the treatment of adult patients with transfusion-dependent anemia requiring at least two RBC units over 8 weeks resulting from very low- to intermediate-risk myelodysplastic syndromes (MDS) who have ring sideroblasts and who have failed or are not suitable for erythropoietin-based therapy.

  • Brand Name: Reblozyl
  • Manufacturer: Celgene Inc., a Bristol Myers Squibb company
  • Project Number: SR0670-000
  • Project Status: Active
  • Submission Type: Initial